Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 7/20 | 0.31 |
| ▸ | GAA | P10253 | 7/20 | 0.31 |
| ▸ | SI | P14410 | 7/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966676 | 0.94 | HDAC1 (0.36) | HDAC1HDAC2ESR1ESR2FFAR4 | |
| SCHEMBL4965912 | 0.86 | FFAR4 (0.32) | LTA4HESR1ESR2FFAR4MGAM | |
| SCHEMBL4965284 | 0.80 | PTGDR2 (0.34) | ESR1ESR2FFAR4 | |
| SCHEMBL4965710 | 0.78 | ESR1 (0.55) | HDAC1HDAC2ESR1ESR2MGAM | |
| SCHEMBL4965002 | 0.74 | ESR1 (0.50) | ESR1ESR2MGAMGAASI | |
| SCHEMBL7589490 | 0.67 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL5851908 | 0.67 | ESR1 (0.54) | ESR1ESR2 | |
| SCHEMBL5851970 | 0.66 | ESR1 (0.61) | ESR1 | |
| SCHEMBL5851880 | 0.66 | ESR1 (0.60) | ESR1 | |
| SCHEMBL5075157 | 0.66 | ESR1 (0.60) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641774-B1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY | 2007-03-08 | — | — | US | claimed |
| US-7462647-B2 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1641774-B1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY | 2007-03-08 | — | — | US | disclosed |
| EP-1641774-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000834-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ESR2, ESR1, GPER1 | HDAC1 2510/4885HDAC2 2386/4885LTA4H 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.